253 related articles for article (PubMed ID: 33082438)
1. Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy.
Lee J; Sheen JH; Lim O; Lee Y; Ryu J; Shin D; Kim YY; Kim M
Sci Rep; 2020 Oct; 10(1):17753. PubMed ID: 33082438
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
3. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
[TBL] [Abstract][Full Text] [Related]
4. A versatile system for rapid multiplex genome-edited CAR T cell generation.
Ren J; Zhang X; Liu X; Fang C; Jiang S; June CH; Zhao Y
Oncotarget; 2017 Mar; 8(10):17002-17011. PubMed ID: 28199983
[TBL] [Abstract][Full Text] [Related]
5. Genome Editing in Clostridium saccharoperbutylacetonicum N1-4 with the CRISPR-Cas9 System.
Wang S; Dong S; Wang P; Tao Y; Wang Y
Appl Environ Microbiol; 2017 May; 83(10):. PubMed ID: 28258147
[No Abstract] [Full Text] [Related]
6. Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System.
Hong CH; Sohn HJ; Lee HJ; Cho HI; Kim TG
J Immunother; 2017; 40(6):201-210. PubMed ID: 28604557
[TBL] [Abstract][Full Text] [Related]
7. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
[No Abstract] [Full Text] [Related]
8. Genome-Edited T Cell Therapies.
Ottaviano G; Qasim W
Hematol Oncol Clin North Am; 2022 Aug; 36(4):729-744. PubMed ID: 35773047
[TBL] [Abstract][Full Text] [Related]
9. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
10. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
Tapscott T; Guarnieri MT; Henard CA
Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 Ribonucleoprotein Complex-Mediated Efficient B2M Knockout in Human Induced Pluripotent Stem Cells (iPSCs).
Thongsin N; Wattanapanitch M
Methods Mol Biol; 2022; 2454():607-624. PubMed ID: 33945142
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
13. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
[TBL] [Abstract][Full Text] [Related]
14. Efficient genome editing of Brassica campestris based on the CRISPR/Cas9 system.
Xiong X; Liu W; Jiang J; Xu L; Huang L; Cao J
Mol Genet Genomics; 2019 Oct; 294(5):1251-1261. PubMed ID: 31129735
[TBL] [Abstract][Full Text] [Related]
15. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.
Xu H; Wang B; Ono M; Kagita A; Fujii K; Sasakawa N; Ueda T; Gee P; Nishikawa M; Nomura M; Kitaoka F; Takahashi T; Okita K; Yoshida Y; Kaneko S; Hotta A
Cell Stem Cell; 2019 Apr; 24(4):566-578.e7. PubMed ID: 30853558
[TBL] [Abstract][Full Text] [Related]
16. [CRISPR-Cas9 mediated genome editing in Caenorhabditis elegans].
Meng X; Zhou H; Xu S
Sheng Wu Gong Cheng Xue Bao; 2017 Oct; 33(10):1693-1699. PubMed ID: 29082717
[TBL] [Abstract][Full Text] [Related]
17. Chromatin accessibility and guide sequence secondary structure affect CRISPR-Cas9 gene editing efficiency.
Jensen KT; Fløe L; Petersen TS; Huang J; Xu F; Bolund L; Luo Y; Lin L
FEBS Lett; 2017 Jul; 591(13):1892-1901. PubMed ID: 28580607
[TBL] [Abstract][Full Text] [Related]
18. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
19. [Research progress of CRISPR-Cas9 system for gene therapy].
Zhan C; Xia X
Sheng Wu Gong Cheng Xue Bao; 2016 Jul; 32(7):861-869. PubMed ID: 29019208
[TBL] [Abstract][Full Text] [Related]
20. The use of CRISPR/Cas associated technologies for cell transplant applications.
Cowan PJ
Curr Opin Organ Transplant; 2016 Oct; 21(5):461-6. PubMed ID: 27517504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
